Press Release Headlines

Kibow Biotech Selected to Give a Presentation on the Impact of Modulation of the Gut Microbiome in Chronic Kidney Disease (CKD) at the International Scientific Conference on Probiotics and Prebiotics – IPC2016

NEWTOWN SQUARE, Pa., June 21, 2016 /PRNewswire/ — This year's International Scientific Conference on Probiotics and Prebiotics (IPC 2016) will be held in Budapest, Hungary – June 21st – 23rd It will focus on the current advances in the science and research of Probiotics/ Prebiotics in the rapidly emerging field "Gut Microbiome" and with a particular focus on their role in maintaining health and preventing diseases (the key mission of this event).   IPC2016 will also focus on evidence ascertained from running clinical trials and scientific experiments. The mission of the IPC 2016 conference is to provide a comprehensive scientific forum to all stakeholders of Probiotic/ Prebiotic businesses. The three-day conference is a networking event for scientists, researchers, product developers, industry participants and regulatory officials (a large portion of who will be from the European Food Safety Authority). More than 400 attendees from 80 different countries are participating at this highly scientific oriented conference.

It is indeed a great recognition and honor for Kibow to be invited to present a talk titled: "Pro/Prebiotics Modulation of Gut Microbiome Towards Chronic Kidney Disease (CKD) Application." Dr. Natarajan Ranganathan – Senior Vice President of Research and Development – will deliver the talk as the "closing pitcher" for the conference. Kibow will also be presenting an abstract titled: "Impact of Gut Microbiome Modulation in People with Chronic Kidney Disease (CKD) – Results of a Survey," with their dietary supplement product "Renadyl" being marketed via their company's website.

Renadyl™, a probiotic and prebiotic dietary supplement, is currently sold via Kibow's own online store ( or This probiotic dietary supplement is known for its ability to target and help reduce the buildup of uremic toxins in the body, thus helping to maintain healthy kidney function, via Kibow's Uremic Toxin Reduction Technology. The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA.

In addition to marketing and sales of Renadyl™ as a dietary supplement, the company is currently exploring the option of advancing the product to prescription drug status by way of adhering to all USFDA guidelines.  This will mandate obtaining the needed Investigator New Drug (IND) process and accomplishing several additional human Randomized Controlled Trials (RCT) in the forthcoming years in USA and possibly in several other countries. As a prescription drug, the product will gain greater acceptance by healthcare professionals and equally increased potential for marketing and sales towards Chronic Kidney Disease applications worldwide.

About Kibow Biotech: Established in 1997, Kibow Biotech specializes in research and development of probiotic/prebiotic dietary supplements. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health. The Company's flagship product, Renadyl™, is currently marketed in the US and Canada, and will progressively be made available worldwide, according to the governmental rules and regulatory authorities of individual countries.

About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®":
Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol consists of a combination of three specific probiotic microbial strains and chosen prebiotics.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Investor & Media Contact:

N. Ranganathan
(610) 353 5130) or Email
Read more news from Kibow Biotech Inc.